Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Mol Biol Rep ; 40(12): 6737-45, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24052234

RESUMO

Epidermal growth factor receptor (EGFR) is deemed to be one of the main molecular targets for diagnosis and treatment of cancer. It has been identified that EGFR involves in pathogenesis of some forms of human cancers. Monoclonal antibodies targeting EGFR could control the tumor cell growth, proliferation, and apoptosis by suppressing the signal transduction pathways. Nanobodies can be regarded as the smallest intact antigen binding fragments, derived from heavy chain-only antibodies existing in camelids. Here, we describe the identification of an EGFR-specific nanobody, referred to as OA-cb6, obtained from immunized camel with a cell line expressing high levels of EGFR. Utilizing flow cytometry (FACS) and blotting methods, we demonstrated that OA-cb6 nanobody binds specifically to EGFR expressing on the surface of A431 cells. In addition, OA-cb6 nanobody potently causes the inhibition of EGFR over expression, cell growth and proliferation. The antibody fragments can probably be regarded as worthwhile binding block for further rational design of anti-cancer therapy.


Assuntos
Receptores ErbB/antagonistas & inibidores , Neoplasias/patologia , Anticorpos de Domínio Único/farmacologia , Animais , Afinidade de Anticorpos/imunologia , Especificidade de Anticorpos , Camelus , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Eletroforese em Gel de Poliacrilamida , Ensaio de Imunoadsorção Enzimática , Receptores ErbB/metabolismo , Citometria de Fluxo , Humanos , Imunidade Humoral/efeitos dos fármacos , Anticorpos de Domínio Único/isolamento & purificação
2.
Artif Cells Nanomed Biotechnol ; 46(1): 89-94, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28296511

RESUMO

Epidermal growth factor receptor variant III (EGFRvIII) is the most common variant of the EGF receptor in many human tumors. This variant is tumor specific and highly immunogenic, thus, it can be used as a target for targeted drug delivery toward tumor cells. The major aim of this study was to develop an EGFRvIII-mediated drug delivery system by anti-EGFRvIII monoclonal antibody (MAb) conjugated to doxorubicin (Dox)-loaded nanostructured lipid carriers (NLC) to enhance the targeting specificity and cytotoxic effect of Dox on EGFRvIII-overexpressing cell line. In our study, Dox was chosen as a hydrophobic cytotoxic drug and drug-loaded nanostructured lipid carriers (Dox-NLC) was prepared by solvent emulsification/evaporation method. In order to conjugate anti-EGFRvIII MAb to Dox-NLC, DSPE-PEG2000-NHS (1,2-distearoylphosphatidylethanolamine-polyethylene glycol 2000-NHS) was used as a linker. Physicochemical characteristics of antibody conjugated Dox-NLC (MAb-Dox-NLC), including particle size, zeta potential, entrapment efficiency and in vitro Dox release were investigated. Cytotoxicity of MAb-Dox-NLC against NIH-3T3 and HC2 20d2/c (EGFRvIII-transfected NIH-3T3) cell lines was evaluated. The MAb-Dox-NLC appeared to enhance the cytotoxic activity of targeted NLC against HC2 20d2/c cells. The cellular uptake percentage of targeted NLC by HC2 20d2/c cells was higher than that of NIH-3T3 cells, indicating that EGFRvIII can specifically target HC2 20d2/c cells. In conclusion, anti-EGFRvIII MAb-targeted NLC may be considered as an effective nanocarrier for targeted drug delivery.


Assuntos
Anticorpos Monoclonais/química , Doxorrubicina/química , Portadores de Fármacos/química , Receptores ErbB/imunologia , Lipídeos/química , Nanoestruturas/química , Animais , Anticorpos Monoclonais/imunologia , Transporte Biológico , Sobrevivência Celular/efeitos dos fármacos , Portadores de Fármacos/metabolismo , Portadores de Fármacos/farmacologia , Liberação Controlada de Fármacos , Camundongos , Células NIH 3T3 , Polietilenoglicóis/química
3.
Artif Cells Nanomed Biotechnol ; 46(3): 524-535, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-28509572

RESUMO

Silibinin is a natural flavonoid with a strong antioxidant property and weak cytotoxic activity. It has demonstrated anti-tumoural activity against many types of malignancies; however, due to its hydrophobic structure, it has poor water solubility, bioavailability and permeability across intestinal epithelial cells. To improve the effect of silibinin, we have vehiculated silibinin by a highly stable niosomal nanostructure based on a Span 60/cholesterol (CH)/N-trimethyl chitosan (TMC) system in order to study its potential application for the delivery of silibinin in T47D cultured under three-dimensional (3D) and two-dimensional (2D) conditions. To study the effect of nanodrug on miRNAs expression, we evaluated quantitative expression of miRNA-21 and miRNA-15a as well as miR-141 and miR-200c which act as oncogene and tumour suppressors by real-time PCR. Results demonstrated that the mechanism of nanodrug action as well as the response of tumour cells differed in 3D culture as compared to 2D. Delivery of silibinin-loaded niosomes coated with TMC was found to be more effective in inhibiting the growth of tumour cells and inducing apoptosis than free silibinin administration. In silibinin-treated cells, death occurred in a dose- and time- dependent manner by induction of apoptosis and alteration of the cell cycle. Real-time PCR analysis revealed a decrease in miR-21, miR-15a and miR-141while increase in miR-200c expression levels was observed in silibinin-treated cells relative to the levels in the untreated cells. The results show that nanodrug delivery was more effective than free silibinin administration in changing the level of miRNAs expression in cancer cells. Therefore, niosomal nanostructure with TMC could be a suitable vehicle for hydrophobic compounds, such as silibinin, by improving their action in cancer therapy.


Assuntos
Neoplasias da Mama , Quitosana , Materiais Revestidos Biocompatíveis , Portadores de Fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , MicroRNAs/biossíntese , Nanopartículas/química , RNA Neoplásico/biossíntese , Silimarina , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Quitosana/química , Quitosana/farmacologia , Materiais Revestidos Biocompatíveis/química , Materiais Revestidos Biocompatíveis/farmacologia , Portadores de Fármacos/química , Portadores de Fármacos/farmacologia , Feminino , Humanos , Silibina , Silimarina/química , Silimarina/farmacologia
4.
IET Nanobiotechnol ; 10(1): 20-7, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26766869

RESUMO

This study presents a novel signal amplification method for high-sensitive electrochemical immunosensing. Gold (Au)/N-trimethyl chitosan (TMC)/iron oxide (Fe3O4) (shell/shell/core) nanocomposite was used as a tracing tag to label antibody. The tag was shown to be capable of amplifying the recognition signal by high-density assembly of Au nanoparticles (NPs) on TMC/Fe3O4 particles. The remarkable conductivity of AuNPs provides a feasible pathway for electron transfer. The method was found to be simple, reliable and capable of high-sensitive detection of human serum albumin as a model, down to 0.2 pg/ml in the range of 0.25-1000 pg/ml. Findings of the present study would create new opportunities for sensitive and rapid detection of various analytes.


Assuntos
Quitosana/química , Técnicas Eletroquímicas/métodos , Compostos Férricos/química , Ouro/química , Nanocompostos/química , Nanopartículas/química , Albumina Sérica/análise , Anticorpos Monoclonais Murinos/química , Humanos , Sensibilidade e Especificidade
5.
Monoclon Antib Immunodiagn Immunother ; 34(4): 270-4, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26301931

RESUMO

A monoclonal antibody (MAb) was produced by immunization of a BALB/c mouse with a conjugated morphine C6-hemisuccinated derivative (MHS) to cationized bovine serum albumin (cBSA). The hybridoma clones were screened by indirect ELISA using MHS-BSA. The best hybridoma clone was subcloned thrice by limiting dilution. This hybridoma was found to be of IgG2b class and subclass and contained lambda light chain. The affinity of the MAb to morphine was obtained 2.8×10(9) M(-1). The titer of the cell culture supernatant was at least 1:800. The MAb was cross-reacted with codeine (100%) and apomorphine (16.5%), but not with heroin, naloxone, naltrexone, or papaverine. Morphine was conjugated to HRP using a mixed anhydride method and a direct competitive ELISA was designed using anti-morphine MAb. The assay was sensitive over the 50 ng/mL to 5 µg/mL concentration range. In conclusion, this MAb is useful for the development of immunoassays to measure morphine in urine.


Assuntos
Anticorpos Monoclonais/imunologia , Morfina/imunologia , Animais , Afinidade de Anticorpos/imunologia , Apomorfina/imunologia , Codeína/imunologia , Reações Cruzadas/imunologia , Ensaio de Imunoadsorção Enzimática/métodos , Hibridomas/imunologia , Imunização/métodos , Imunoensaio/métodos , Imunoglobulina G/imunologia , Camundongos , Camundongos Endogâmicos BALB C
6.
Iran J Allergy Asthma Immunol ; 14(1): 113-9, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25530147

RESUMO

Alkylhydroperoxide reductase (AhpC, the 26 kDa antigen) is one of the abundant antioxidant enzymes in Helicobacter pylori and seems to have a good potential for use in development of immunoassays to detect H. pylori infection in clinical specimens. This study aimed to investigate some properties of this antigen by the produced monoclonal antibodies. Five established hybridoma cell lines secreting monoclonal antibodies (MAbs) against 26 kDa antigen of H. pylori were cultivated and MAbs were purified by affinity chromatography. Subsequently, MAbs were conjugated with biotin, and different combinations of capture and tracer antibodies used in sandwich ELISA. Immunoblotting of bacterial extracts were performed to estimate aggregation status of the antigen. Release of antigen from the cultivated bacteria on solid media was examined by sandwich ELISA, and also, existence of interference in fecal extract was investigated by immunoblotting and sandwich ELISA. Our findings showed that the MAbs against 26 kDa antigen of H. pylori could recognize three bands of nearly 25 kDa, 50 kDa, and 75 kDa in immunoblotting. This study also indicated presence of more antigens in the culture medium around the bacteria than the bacterial extract itself. The results of sandwich ELISA and immunoblotting on fecal extracts suggest the presence of interfering agents that prevent detection of antigen by antibody in ELISA but not in immunoblotting. In this study the oligomerization of the 26 kDa antigen, presence of interfering agents in stool matrix, and release of antigen to outside of bacteria, were demonstrated.


Assuntos
Anticorpos Monoclonais , Proteínas de Bactérias/isolamento & purificação , Infecções por Helicobacter/diagnóstico , Peroxidases/isolamento & purificação , Ensaio de Imunoadsorção Enzimática , Fezes/microbiologia , Humanos
7.
Mater Sci Eng C Mater Biol Appl ; 46: 333-40, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25491995

RESUMO

This study reports the development of a highly stable niosomal nanostructure based on Span 60/cholesterol (CH)/N-trimethyl chitosan (TMC) system and its potential application for oral delivery of insulin. Insulin loaded niosomes were prepared by reversed-phase evaporation and TMC coating was performed by incubation of niosomal suspensions with TMC solution. The efficiency of nanoparticulate delivery system in enhancement of insulin permeation was evaluated by Caco-2 cell monolayer as intestinal membrane models. The prepared niosomes were characterized for entrapment efficiency (EE), particle size, zeta potential and stability. The particles were between 100 and 180 nm in diameter, and they were stable for over 60 days at 4 °C. Insulin permeability through Caco-2 cell monolayer was enhanced 4-fold by niosomal nanoparticles, compared with insulin alone. Further work is demanded to optimize this formulation with the object of maximizing its potential to facilitate oral delivery of insulin.


Assuntos
Quitosana/administração & dosagem , Insulina/metabolismo , Mucosa Intestinal/metabolismo , Modelos Biológicos , Materiais Biocompatíveis , Células CACO-2 , Portadores de Fármacos , Humanos
8.
Appl Biochem Biotechnol ; 160(3): 843-55, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19224402

RESUMO

Digoxin is widely used as a cardiac glycoside drug in the treatment of various heart conditions. Because it is a toxic drug, it should be regularly monitored in the serum of patients under treatment. In this study, colloidal nanogold is synthesized and the preparation of nanogold-labeled monoclonal antibody probe to digoxin is described under optimal conditions. In addition, an immunochromatographic (IC) method for digoxin analysis employing nanogold-labeled probe is developed. With this technique, it requires only 5 min to complete the quantitative detection of digoxin. The detection time is decreased 20-30 times in comparison to radioimmunoassay (RIA). The sensitivity to digoxin was about 2 ng/ml by naked eye, which is within the therapeutic and toxic ranges of digoxin. The results of serum samples obtained by IC strip were in agreement with those obtained by RIA. The IC strip was sufficiently sensitive and accurate to be used for the rapid detection of digoxin in serum samples.


Assuntos
Digoxina/toxicidade , Ouro/química , Imunoensaio/métodos , Nanopartículas Metálicas/química , Fitas Reagentes , Animais , Anticorpos Monoclonais/química , Anticorpos Monoclonais/imunologia , Bovinos , Cromatografia , Coloides , Digoxina/análise , Digoxina/imunologia , Digoxina/metabolismo , Humanos , Radioimunoensaio , Soroalbumina Bovina/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA